(Q41393684)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26347128%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

title

Drug-induced progressive multifocal leukoencephalopathy: Lessons learned from contrasting natalizumab and rituximab (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26347128%20AND%20SRC:MED&resulttype=core&format=json

progressive multifocal leukoencephalopathy

23 February 2020

main subject

1 reference

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26347128%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Marie Louise De Bruin

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26347128%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

author name string

N S Vermeer

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26347128%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

S M J M Straus

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26347128%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

A K Mantel-Teeuwisse

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26347128%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

A Hidalgo-Simon

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26347128%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

H G M Leufkens

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26347128%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

language of work or name

English

0 references

publication date

8 September 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26347128%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

23 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26347128%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

volume

98

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26347128%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26347128%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

page(s)

542-550

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26347128%20AND%20SRC:MED&resulttype=core&format=json

Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis

23 February 2020

cites work

1 reference

Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases

21 January 2018

1 reference

Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study.

21 January 2018

1 reference

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

21 January 2018

1 reference

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

21 January 2018

1 reference

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

21 January 2018

1 reference

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

21 January 2018

1 reference

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

21 January 2018

1 reference

Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents

21 January 2018

1 reference

Signals of progressive multifocal leukoencephalopathy for immunosuppressants: a disproportionality analysis of spontaneous reports within the US Adverse Event Reporting System (AERS).

21 January 2018

1 reference

Expecting the unexpected--drug safety, pharmacovigilance, and the prepared mind.

21 January 2018

1 reference

Tolerability and safety of rituximab (MabThera).

21 January 2018

1 reference

Progressive multifocal leukoencephalopathy during treatment with rituximab and CHOP chemotherapy in a patient with a diffuse large B-cell lymphoma

21 January 2018

1 reference

Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab

21 January 2018

1 reference

Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias

21 January 2018

1 reference

Impact of television coverage on the number and type of symptoms reported during a health scare: a retrospective pre-post observational study

21 January 2018

1 reference

Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies

21 January 2018

1 reference

QUINIDINE SYNCOPE. PAROXYSMAL VENTRICULAR FIBRILLATION OCCURRING DURING TREATMENT OF CHRONIC ATRIAL ARRHYTHMIAS.

21 January 2018

1 reference

Drug-induced prolongation of the QT interval

21 January 2018

1 reference

Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw.

21 January 2018

1 reference

Osteonecrosis of the jaw--do bisphosphonates pose a risk?

21 January 2018

1 reference

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

21 January 2018

1 reference

Strategy in Regulatory Decision-Making for Management of Progressive Multifocal Leukoencephalopathy.

21 January 2018

1 reference

Progressive multifocal leukoencephalopathy in multiple sclerosis

21 January 2018

1 reference

Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research

21 January 2018

1 reference

Progressive multifocal leukoencephalopathy

21 January 2018

1 reference

7 January 2021

Drug-induced PML: a global agenda for a global challenge

1 reference

7 January 2021

PML problems loom for Rituxan

1 reference

7 January 2021

Discovering adverse reactions: why does it take so long?

1 reference

7 January 2021

Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody

1 reference

7 January 2021

Progressive multifocal leukoencephalopathy after allogeneic stem cell transplantation and posttransplantation rituximab

1 reference

7 January 2021

Identifiers

DOI

10.1002/CPT.207

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26347128%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference